13F Holdings
中文EN

ERNA Ernexa Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 748592 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY755.9%
TTM net income YoY-105.6%
TTM EPS YoY-1,100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin83.5%
Operating margin-2,693.1%
Net margin-7,652.7%
FCF margin-2,784.4%
EBITDA margin-2,648.8%

Returns

ROE-2,264.3%
ROA-163.7%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets67.7%
Debt / equity0.00x
Current ratio0.80x
Interest coverage2.09x

Cash quality & payout

Operating cash flow / net income0.36x
Accruals ratio-105.5%
Payout ratio—
Capex / revenue63.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—$582,000$68,000$0—
Cost of revenue—$96,000$236,000$0—
Gross profit—$486,000-$168,000$0—
R&D expense$4.16M$4.60M$5.92M$10.39M$12.71M
SG&A expense$5.16M$13.13M$14.59M$16.84M$14.72M
Operating income-$9.32M-$15.67M-$21.14M-$33.22M-$113.73M
Interest expense-$100,000-$6.80M$500,000$30,000—
Pretax income-$14.13M-$44.51M-$21.67M-$24.53M-$122.48M
Income tax-$45,000$30,000-$3,000$45,000$64,000
Net income-$14.08M-$44.54M-$21.67M-$24.58M-$122.55M
EBITDA-$9.25M-$15.54M-$21.05M-$33.06M-$113.61M
EPS (basic)-2.24-48.96-4.08-8.06-56.61
EPS (diluted)-2.24-48.96-4.08-8.06-56.61
Weighted avg. shares (diluted)6.31M910,0005.31M3.05M2.17M
Balance sheet
Cash & equivalents$1.88M$1.73M$11.67M$15.54M$16.98M
Receivables————$684,000
Current assets$3.13M$2.35M$9.60M$13.68M$18.77M
PP&E, net$94,000$85,000$493,000$236,000$670,000
Goodwill$2.04M$2.04M$2.04M$2.04M$2.04M
Total assets$5.83M$5.27M$49.13M$22.28M$31.52M
Current liabilities$3.11M$2.94M$6.57M$7.65M$3.68M
Total liabilities$3.43M$3.57M$46.90M$10.17M$6.02M
Shareholders' equity$2.40M$1.70M$2.23M$12.11M$25.50M
Shares outstanding314,0003.43M5.41M5.13M2.60M
Cash flow statement
Operating cash flow-$7.02M-$15.84M-$20.41M-$20.98M-$23.49M
Capital expenditure$37,000$369,000$19,000$297,000$154,000
Free cash flow-$7.05M-$16.20M-$20.43M-$21.27M-$23.64M
Investing cash flow-$37,000-$365,000-$19,000-$47,000-$22.74M
Financing cash flow$7.21M$6.26M$16.56M$19.58M$61.59M
Depreciation & amortization$65,000$139,000$84,000$161,000$117,000
Stock-based compensation$1.50M$1.52M$1.24M$2.94M$5.24M

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.